Comparative analysis of primary versus relapse/refractory DLBCL identifies shifts in mutation spectrum.
Greenawalt DM, Liang WS, Saif S, Johnson J, Todorov P, Dulak A, Enriquez D, Halperin R, Ahmed A, Saveliev V, Carpten J, Craig D, Barrett JC, Dougherty B, Zinda M, Fawell S, Dry JR, Byth K.
Greenawalt DM, et al. Among authors: saveliev v.
Oncotarget. 2017 Jun 15;8(59):99237-99244. doi: 10.18632/oncotarget.18502. eCollection 2017 Nov 21.
Oncotarget. 2017.
PMID: 29245897
Free PMC article.